5-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-2-phenyl-1,3-thiazole

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-2-phenyl-1,3-thiazole
• 化学式: C₁₆H₁₉N₃S
• 分子量: 285.4
• InChiKey: KTZBXHQABAEHNW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  47.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• 4-(2 phenylthiazol-5-yl)-1, 4-diazabicyclo-[3.2.2]nonane deirvatives, preparation and therapeutic use thereof
  申请人：——

  公开号：US20040029884A1

  公开（公告）日：2004-02-12

  Compound corresponding to the general formula (I) 1 in which R 1 , R 2 , R 3 , R 4 and R 5 each represent a hydrogen or halogen atom or a nitro, amino, trifluoromethyl, trifluoroalkoxy, cyano, hydroxyl, (C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy group and R 6 represents a (C 1 -C 6 )alkyl group. Therapeutic application.

  具有一般化学式(I)的化合物，其中R1、R2、R3、R4和R5分别代表氢或卤素原子，或硝基、氨基、三氟甲基、三氟烷氧基、氰基、羟基、(C1-C6)烷基或(C1-C6)烷氧基基团，R6代表(C1-C6)烷基基团。治疗应用。
• [EN] DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS<br/>[FR] COMPOSES DIAZABICYCLIQUES UTILISES DANS LE TRAITEMENT DE TROUBLES ASSOCIES AU SNC
  申请人：PFIZER PROD INC

  公开号：WO2004024729A1

  公开（公告）日：2004-03-25

  The present invention relates to a compounds of formula (I): wherein A, B, D, E and F are defined herein; that are useful in treating central nervous system (CNS) diseases, disorders and conditions, such as but not limited to nicotine addiction, schizophrenia, depression, Alzheimer's disease, Parkinson's disease and ADHD. The present invention further comprises pharmaceutical compositions containing such compounds and methods of treatment comprising the use of such compounds.

  本发明涉及公式(I)的化合物：其中A、B、D、E和F在此处定义；这些化合物在治疗中枢神经系统（CNS）疾病、紊乱和症状方面具有用处，例如但不限于尼古丁成瘾、精神分裂症、抑郁症、阿尔茨海默病、帕金森病和注意力缺陷多动障碍。本发明还包括含有这些化合物的药物组合物和包括使用这些化合物的治疗方法。
• [EN] 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO[3,4-f]QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS<br/>[FR] COMPOSES 5-SUBSTITUES DE 7,9-DIFLUORO-5H-CHROMENO[3,4-F]QUINOLINE MODULATEURS DU RECEPTEURS DE LA PROGESTERONE SELECTIFS
  申请人：LIGAND PHARM INC

  公开号：WO2004033461A1

  公开（公告）日：2004-04-22

  The present invention is directed to compounds of formula (I) or (II), pharmaceutical compositions, and methods for modulating processes mediated by progesterone receptor. Also provided are methods of making such compounds and pharmaceutical compositions.

  本发明涉及式(I)或(II)化合物、药物组合物以及调节孕激素受体介导过程的方法。还提供了制备这种化合物和药物组合物的方法。
• Diazabicyclic compounds useful in the treatment of CNS and other disorders
  申请人：Pfizer Inc

  公开号：US20040106603A1

  公开（公告）日：2004-06-03

  The present invention relates to a compounds of formula I: 1 wherein A, B, D, E and F are defined herein; that are useful in treating central nervous system (CNS) diseases, disorders and conditions, such as but not limited to nicotine addiction, schizophrenia, depression, Alzheimer's disease, Parkinson's disease and ADHD. The present invention further comprises pharmaceutical compositions containing such compounds and methods of treatment comprising the use of such compounds.

  本发明涉及一种化合物，其化学式为I：1，其中A、B、D、E和F的定义如下；该化合物可用于治疗中枢神经系统（CNS）疾病、紊乱和病况，例如但不限于尼古丁成瘾、精神分裂症、抑郁症、阿尔茨海默病、帕金森病和ADHD。本发明还包括含有这种化合物的制药组合物和使用这种化合物的治疗方法。
• DERIVES DE 4-(2-PHENYLTHIAZOL-5-YL)-1,4-DIAZABICYCLO- 3.2.2]NONANE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI-SYNTHELABO

  公开号：EP1289987A1

  公开（公告）日：2003-03-12